Tampa will be the big issue in 2017

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Dec 21, 2016 at 10:54 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The plant is in shambles and can't get product to pass quality. So many of the products made there are on back order, and will continue to be on back order until at least the second quarter.
     

  2. anonymous

    anonymous Guest

    I thought Papa hired an executive dedicated to QC.
     
  3. anonymous

    anonymous Guest

    He's as crooked as the rest. Fake resume, good b.s artist, poor execution, that's the talent that papa is hiring. Basically, he's hiring folks based on his mold.
     
  4. anonymous

    anonymous Guest

    What do they make there?
     
  5. anonymous

    anonymous Guest

    "Shambles" means a bomb blew it up. Clearly that is untrue.

    What specifically is wrong with the plant?
     
  6. anonymous

    anonymous Guest

    Tampa is the US ophthalmic pharmaceutical production plant for Bausch and Lomb. The site has experienced a complete loss of all competent management in all areas since Valeant acquisition.
    The site received its worst FDA audit response in its history in 2016 due to its inability to routinely produce quality sterile products and adequately investigate customer complaints. The FDA also tendered a complete response letter to a recent NDA related to their concerns of the Tampa facility...
     
  7. anonymous

    anonymous Guest

    A little training, cleanup and patience, and we'll be running like a fine tuned machine in no time. Stop making this a bigger deal than it really is. People here are trying our best, but the extra scrutiny is probably politically motivated. Just please don't shut us down.
     
  8. anonymous

    anonymous Guest

    Tampa has no leadership thus no direction. The production cost have skyrocketed due to the number of rejected batches. The production delays have extended the back order delays. The QC lab is now occupied by contract staff. No R&D so no new products.

    Tampa is an excellent example as to why Valeant will not regain its investments when its assets will be sold - which is a requirement to service its debt!
     
  9. anonymous

    anonymous Guest

    stop making this a bigger deal.. really?
    The FDA audit and the complete response letter identify the severity of the current state. the lack of response - and continued growth of production inefficiency - provide a glimpse into the future state.
     
  10. anonymous

    anonymous Guest

    These issues probably existed before the acquisition. All bad crap bubbles to the surface eventually. Ideally, move all manufacturing to lower cost countries, since those guys are probably unionized and overpaid.
     
  11. anonymous

    anonymous Guest

    True Many good people left.
    It will take more than a little help but it can be done. Tampa's downfall is that the FDA looks harder at everything Valeant. They skated by in the past and got complacent. They got caught this time.
    Valeant thinks everything can be contracted out with no overhead. They end up getting less work for more money than if they just hired people. They still contract out key management and technical jobs for big bucks. Meanwhile, good employees walk out the door.
    Agree. they got caught this time but labor is pretty cheap. Pretty sure they are not a union shop.
     
  12. anonymous

    anonymous Guest

    you left out lipstick.
     
  13. anonymous

    anonymous Guest

    And pig.
     
  14. anonymous

    anonymous Guest

    interestingly very silent following recent big management change in Tampa...
     
  15. anonymous

    anonymous Guest

    Thank goodness and hopefully they will get things on track.
     
  16. anonymous

    anonymous Guest

    What happened? Are the new people any good?
     
  17. anonymous

    anonymous Guest

    This is Valeant. If they are good, it's only by accident. And they won't stay...